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Abstract Unwanted pregnancy is a major public health problem both in developed and
developing countries. Although the reduction in the rates of these pregnancies
requires multifactorial approaches, increasing access to long-acting contraceptive
methods can contribute significantly to change this scenario. In Brazil, gynecologists
and obstetricians play a key role in contraceptive counseling, being decisive in the
choice of long-acting reversible methods, characterized by intrauterine devices (IUDs)
and the contraceptive implant. The vast scope due to the reduced number of situations
to indicate long-acting methods should be emphasized in routine contraceptive
counseling. On the other hand, gynecologists and obstetricians should adapt the
techniques of insertion of long-actingmethods, and engage in facilitating conditions to
access these contraceptives through public and private health systems in Brazil. This
study is part of a project called Diretrizes e Recomendações FEBRASGO (Guidelines and
 This revision is part of the Project Series, Guidelines and
Recommendations of the Federação das Associações de Ginecologia
e Obstetrícia - FEBRASGO, elaborated by the Specialized National
Committees in Contraception.
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Introduction
Prevalence and Social-medical Impact of Unintended
Pregnancy
Unwanted pregnancies affect a large number of women in
the world and in Brazil. Surveys have observed an average
worldwide pregnancy rate of 133 in every 1,000women aged
15–44, but  40% of them, 53 in every 1,000, are unintend-
ed.1 The highest incidence is in Latin America, the Caribbean
and Africa, reaching rates above 60% of pregnancies.1
More than 200 million women living in developing coun-
tries want to avoid pregnancy, but unfortunately do not use
any contraceptive method.2 In Brazil, in 2006, data from the
National Survey on Demography and Health of Children and
Women showed that only 54% of women had planned their
pregnancies, and 18% of pregnancies were unwanted.3 More
recently, it was observed that 55.4% of Brazilian pregnant
women did not want to be pregnant at that time.4 Unintend-
ed pregnancy is defined as untimely or unwanted at the time
of conception.1Knowledge about the pregnancy is important
because it can result in adverse effects for both the mother
and the fetus.5 These data may help especially developing
countries, where maternal morbidity and mortality are
higher.
Despite the difficulty of establishing causal relationships,
some studies have found an association between unwanted
pregnancy and negative repercussions in the maternal and
fetal health sphere, as well as in the economic and social
health spheres.5 These are considered risky pregnancies for
their frequent association with some type of habit or obstet-
rical disorder.6 The most frequently observed alterations are
inadequate prenatal care or delayed start of prenatal care, no
reduction or interruption of smoking/alcohol use, increased
incidence of abortion, prematurity, low birth weight and
lower chance of breastfeeding.6
Studies have showna strong associationbetweenaltered or
poor qualitymental health inwomen and unwanted pregnan-
cies. Especially in those situations inwhich the couple already
had the desired number of children.7 The prevalence of
psychiatric illnesses, such as depression, is twice as high
among women who did not plan their pregnancies when
compared to those who planned them.7 Studies suggest that
unwanted pregnancy reduces the opportunities of education
andwork, contributing to reduced socioeconomic growth and,
consequently, theworsening of social inequalities. This issue is
considered one of the great challenges for the public health
system, because it is responsible for a significant financial and
social cost to society.5
Unwanted pregnancies can be reduced through quality of
life improvement programs. The most effective programs
and with the best socioeconomic results are those acting in
the training and education of individuals. The implementa-
tion of preventive measures, such as promoting health
information, improving and adapting care systems, and
expanding techniques for women’s treatment and follow-
up is also necessary. Prevention through contraceptivemeth-
ods is an effective way that can bring good results. One of the
main causes of unwanted pregnancy is the unmet need for
contraception. The lack of contraceptive methods, the
Recommendations of the FEBRASGO – Brazilian Federation of Gynecology and Obstetrics
Associations from the Portuguese acronym). It aims to review the main characteristics
of long-acting contraceptives and critically consider the current situation and future
prospects to improve access to these methods, proposing practical recommendations
of interest in the routine of gynecologists and obstetricians.
Resumo A gravidez não planejada representa importante problema de saúde pública tanto em
países desenvolvidos quanto naqueles em desenvolvimento. Embora a redução das
taxas dessas gestações requeira abordagens multifatoriais, o aumento no acesso aos
métodos contraceptivos de longa ação pode contribuir de forma expressiva na
mudança desse cenário. No Brasil, os ginecologistas e obstetras têmpapel fundamental
no aconselhamento contraceptivo, sendo decisivos na escolha dos métodos reversíveis
de longa ação, caracterizados pelos dispositivos intrauterinos (DIUs) e pelo implante
anticoncepcional. A grande abrangência decorrente do pequeno número de situações
que contraindicam os métodos de longa ação deve ser enfatizada no aconselhamento
contraceptivo de rotina. Por outro lado, os ginecologistas e obstetras devem se adaptar
às técnicas de inserção dos métodos de longa ação, bem como se engajar na facilitação
de condições para o acesso a esses contraceptivos por meio do sistema de saúde
pública e privada no Brasil. Este estudo, parte do projeto denominado “Diretrizes e
Recomendações FEBRASGO”, tem por objetivo revisar as principais características dos
contraceptivos de longa ação, além de considerar de forma crítica o panorama atual e
as perspectivas futuras, visando melhorar o acesso a esses métodos, com recomenda-
ções práticas de interesse na rotina do ginecologista e obstetra.
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existence of few options, and the incorrect use of the
contraceptive system lead to unwanted pregnancy. Thus,
the chosen method and the frequency and type of use over
time can reduce this risk. Among the available contraceptive
options, long-acting methods are the main interventions for
reducing unwanted pregnancies, especially in the groups
that are at risk, given their high efficacy. By definition, long-
acting reversible contraceptives (LARCs) last for three years
or more, and are represented by intrauterine devices (IUDs,
such as copper IUDs and the levonorgestrel intrauterine
system [LNG-IUS]) and the contraceptive implant.8
Methods
This literature review has the objective of offering theoret-
ical and practical knowledge about long-acting reversible
contraceptive methods. The selected topics are related to
effectiveness, safety, ethical-legal aspects and practical
applicability.
PubMed was the searched database by using Medical
Subject Headings (MeSH) that suggested treatment outcome
for contraceptives, contraceptive agents, female or contracep-
tive agents, female (pharmacological action). Other related
terms included intrauterine devices or intrauterine devices,
medicated and 3-keto-desogestrel (supplementary concept).
The generic keyword long-acting reversible contraceptivewas
also used. The Brazilian legislation was also consulted,
including the Brazilian Civil Code and the Statute of the
Child and Adolescent (ECA, in the Portuguese acronym), as
well as resolutions from the government and specialties
societies, which were verified by bibliographical survey or
quotes on the internet.
All relevant studies published until October 2016 were
included. The bibliographic references of the selected articles
were also used. The classification of the studies followed the
classification of the Brazilian Medical Association (AMB, in
the Portuguese acronym) regarding the degree of recom-
mendation: (A) observational or experimental studies of
better consistency (meta-analysis or randomized clinical
trials); (B) less consistent observational or experimental
studies (other non-randomized clinical trials or observation-
al studies or case control studies); (C) reports or case series
(uncontrolled studies); and (D) opinion devoid of critical
evaluation based on consensus, physiological studies or
animal models.
Results and Discussion
Principles of Long-Acting Reversible Contraceptives
Effectiveness
Compared with short-acting methods, LARCs are superior in
terms of efficacy, providing pregnancy rates of less than 1%
per year in perfect and typical use (A).8 One of the main
advantages of LARCs in relation to short-acting reversible
contraceptives is the maintenance of their high efficacy
regardless of the user’s motivation. Long-acting reversible
contraceptives are independent of the physicians’ or the
user’s action to maintain their efficacy, and have the highest
rates of satisfaction and continuity of use among all revers-
ible contraceptives.
The etonogestrel contraceptive implant is the only avail-
able type in Brazil, and it has a failure rate of 0.05% and
duration of 3 years(A).9 The copper IUD is very effective as a
contraceptive, with a failure rate ranging from 0.6 to 0.8% in
the first year of use, and up to 10 years of action (A).9 Recent
studies confirm the high efficacy of the LNG-IUS, which has
been associated with pregnancy rates ranging from 0 to 0.6%
of women/year (D).10
Indications
Long-acting reversible contraceptives are recommended for
all women who desire effective contraception, including
adolescents, nulliparous, women in the postpartum or
post-abortion periods, and in comorbidities that may char-
acterize contraindications to estrogen-containing methods
(D).11 Thus, the great scope of LARCs can be attested by the
small number of contraindications of these methods.►Fig. 1
shows both the conditions inwhich LARCs are recommended
and not recommended (D).12
Acceptance and Continuity
Long-acting reversible contraception methods maintain
their high efficacy regardless of the users’ motivation, unlike
short-acting reversible contraceptivemethods, which rely on
correct use to achieve high efficacy. Because of their typical
ease of use, LARCs were dubbed ‘get it and forget it’ (B).13
Contraception experts believed the high rates of unwant-
ed pregnancies could be reduced by increasing access to
LARCs (D).14 The Contraceptive CHOICE Project was con-
ducted with this objective. It is a prospective cohort that
broke themain barrier to use LARCs: the cost. The purpose of
the CHOICE Project was to evaluate the satisfaction and
continuity rates among all reversible contraceptivemethods,
including LARCs (B).15
The CHOICE results coincided with the experts’ thinking:
continuity and satisfaction rates were higher among LARC
users (in all age groups) when compared with short-acting
contraceptivemethods (86.2% versus 54.7%, and 83.7% versus
52.7% respectively). It is important to note that most partic-
ipants of the CHOICE Project had low income, were at high
risk for unwanted pregnancies, and 41.8% of the study
participants had had at least one abortion (B).15 The overall
discontinuity rate was higher among adolescents (14–19
years of age) compared with adult women (> 25 years of
age). In addition, for two years, two-thirds of adolescent
LARC users continued with their method, while only a third
of short-acting method users continued to use their method
in the same period. Adolescents in the CHOICE study had a
lower rate of satisfaction with short-acting methods com-
pared with adult women. However, satisfaction rates among
LARC users were high and similar among adolescents and
adult women (B).16
►Table 1 shows the higher continuity rate among LARC
users compared with users of short-acting methods for two
years (B).17,18
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Continuity rates above 80% in the first year of use are also
reported in other populations, always associated to adequate
prior counseling on all contraceptivemethods (B).19A Brazil-
ian study has observed a trend in the past 15 years of more
women continuing to use LARCs and depot medroxyproges-
terone acetate (DMPA) until menopause rather than under-
going surgical sterilization, either in them or in their
partners. There was also a reduction in female and male
sterilization rates in the service. The authors attribute the
high continuity rate of LARCs and DMPA observed in the
study to the appropriate orientation regarding the high
efficacy of these methods (B).20
Higher continuity rates were associated to the beginning
of the use of a LARCmethod in the postpartum period and to
higher satisfaction rates (C).21 A study with American stu-
dents found higher acceptance rates of LARCs among ado-
lescents with previous history of vaginal intercourse and
younger age (C).22
Counseling and Barriers to Access to Long-acting
Methods
There are numerous advantages to LARCs, but their use is still
below what is expected due to myths among patients and
health professionals.
Counseling is critical to increase the continuity rate of the
method. A national study evaluating the efficacy of conven-
tional counseling versus intensive counseling among women
who chose LARCs did not observe a difference in discontinuity
rates between groups. In this study, conventional counseling
Fig. 1 Clinical conditions represented by categories of Medical Eligibility Criteria for contraceptive use.
Table 1 Continuity rate of reversible contraceptive methods in
the first and second year of use according to different studies
Method WHO18 –
1st year %
CHOICE13 –
1st year %
CHOICE13 –
2nd year %
Pills 67 59 43
Ring 67 56 41
Patch 67 49 39
Injectables 56 57 38
Copper IUD 78 85 77
LNG-IUS 80 88 78
Implant 84 83 68
Abbreviations: IUD, intrauterine device, LNG-IUS, levonorgestrel
intrauterine system; WHO, World Health Organization.
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consisted of verbal guidance on mechanism of action, safety,
efficacy, how andwhen fertility returns, adverse effects of the
chosen method, and its non-contraceptive benefits.
For intensive counseling, in addition to information from
conventional counseling, a leaflet was provided with a
picture of the pelvic anatomy, further explanation of changes
in bleeding patterns that could occur during the use of the
chosen method, the mechanism of action of menstrual
irregularities, and the possibilities of treatment. The authors
concluded that routine counseling appears to be sufficient
among the majority of women to help improve the rates of
continuity and satisfaction among new LARC users (A).23
On the other hand, a study comparing the acceptance of
LARCs among post-abortion women undergoing a motiva-
tional interview versus common counseling (control) found
that more than twice as many women in the intervention
group chose and continued to use LARCs (60% versus 31%).
Motivational interviewing is a kind of patient-centered
counseling that includes reflective listening, open discussion
about the advantages and disadvantages of contraceptive
methods, always avoiding confrontation, to promote the
patients’ own motivation for behavior change. Women in
the intervention group also reported higher rates of satisfac-
tion with counseling than those in the control group (92%
versus 65%) (A).24
Studies have shown that the continuity and satisfaction
rates with the contraceptive method are greater when the
decision is made by the patient. Women prefer to decide on
their contraceptivemethod autonomously,with less influence
of the health professional, and after appropriate advice (B).25
Thus, it is important to explain about all methods clearly
and objectively, so patients make an informed decision.
Women selected for the CHOICE study received brief infor-
mation from a trained professional on the duration, efficacy,
and site of implantation of all LARCs (B).26 After this orien-
tation and eliminating the cost of medications, of the 5,087
women included in the study, 68% chose LARCs, 23% chose
combined hormones, and 8% chose medroxyprogesterone
acetate (B).13 The training of health professionals is also
fundamental to reduce barriers and increase access to LARCs.
A study was conducted in 40 family planning services for
low-income population in several American cities. It found
the training of service providers had increased the counsel-
ing, selection and initiation of LARCs among adolescents and
young adults compared with women in service settings that
did not receive training (start of LARCs: 27% versus 12% for
adolescents, and 28% versus 18% for young adults). The
intervention was a continuing education course that lasted
for half a day based on eligibility criteria and clinical cases,
and a practical training to insert IUDs and implants (A).27 The
American College of Obstetricians and Gynecologists (ACOG)
recommends that health professionals provide guidance on
LARCs in all consultations with sexually active adolescents.
Long-acting reversible contraceptives should be the first line
of contraceptive option for them, due to the high risk of
unwanted pregnancy in this age group (D).28 The experience
and training of health professionals with LARCs is directly
proportional to their supply. A study with more than 1,000
American gynecologists and obstetricians has shown that
95% of the interviewees offer IUDs to patients, while only half
of those interviewed offer contraceptive implants. During
medical residency, 92%were trained for IUDs, while only 50%
were trained for their implantation. Continuing education in
the last two years was the most associated variable with
provision of contraceptive implants, and 32% of interviewees
reported lack of training on insertion as a barrier (B).29
A study with over 200 gynecologists and obstetricians in
Latin America on the knowledge of IUDs found deficiencies
and contradictions regarding their knowledge and attitudes.
Of the participants, 10% did not recognize the high efficacy of
LARCs, 80% answered they did not offer IUDs for nulliparous
women, and almost 10% did not offer them for adolescents,
even though 90% of respondents reported that nulliparous
women are candidates for LNG-IUS (B).30 In addition to the
importance of appropriate counseling to increase access to
LARCs, other barriers need to be overcome, such as the high
cost of the medications. Studies have shown that LARCs are
themost cost-effective reversiblemethods, although theyare
still inaccessible to the low-income population (B).31
The most commonly mentioned barrier for the use of
LARCs is the cost of the medications (63%), followed by the
women’s lack of knowledge about their safety, acceptability,
and expectations. The shortage of trained health professio-
nalswas a commonly cited barrier, especially among primary
health care providers (49%) (D).32
Clinical Features, Indications and Clinical
Management with Long-acting Reversible Methods
Levonorgestrel Intrauterine System
The LNG-IUS has a reservoir containing 52 mg of levonor-
gestrel, measures 32 mm in length, and releases 20 μg of
levonorgestrel per day. Through the control membrane, the
system releases levonorgestrel, which starts circulating in
the plasma 15 minutes after insertion. The release rate of
20 μg/day drops throughout use, stabilizing at around
12–14 μg/day, until finally reaching 11 μg/day at the end of
5 years, the recommended time for using LNG-IUS (D).33
According to Luukkainen and Toivonen (D),34 the main mech-
anismsofaction that collaborate toobtaina contraceptivewith
fewer side effects and high effectiveness are the following:
• thick cervical mucus hostile to sperm penetration, inhib-
iting the sperm’s motility in the cervix, endometrium and
fallopian tubes, preventing fertilization;
• high levonorgestrel concentration in the endometrium,
preventing response to circulating estradiol;
• strong anti-proliferative effect in endometrium;
• inhibition of mitotic activity in the endometrium; and
• maintenance of estrogenic production, enabling good
vaginal lubrication.
As a result of these various contraceptive actions, the
effectiveness rate of LNG-IUS is very high, and in several
clinical studies representing over 100,000 women/year/use,
a Pearl index of 0.1 was obtained (A).35 Thus, the LNG-IUS has
excellent contraceptive efficacy and equivalent performance
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for both ‘correct’ and ‘habitual’ use (B) (A).36 Its satisfaction
rate showed indexes higher than 75% in the first year (A).37
One of themain points of the LNG-IUS is its local action on
the endometrium, leading to endometrial atrophy. This
endometrial atrophy allows the appearance of clinical effects
such as amenorrhea and/or oligomenorrhea, which differen-
tiate it from patients using copper IUDs (A).36 Simply put, the
beneficial effects of the LNG-IUS are the following:
• increased hemoglobin concentration;
• it is an effective treatment for menorrhagia;
• it is an alternative to hysterectomy and endometrial
ablation;
• it prevents anemia;
• it can be used in endometrial protection for hormone
replacement therapy; and
• it minimizes the effects of tamoxifen on the endometrium.
With these non-contraceptive effects, LNG-IUS can offer
alternatives to the treatment of menorrhagia, endometrial
hyperplasia and adenomyosis. It offers good results in im-
proving symptoms and menstrual pattern in women with
endometriosis and uterine fibroids (C).38
Clinical Management
The use of LNG-IUS may present some complications and,
although not so frequent, these possibilities should be dis-
cussed before insertion. Anticipatory guidance on possible
side effects helps to achieve better user acceptance, good
results and, consequently, a higher rate of continuity of use of
LNG-IUS. In addition, anticipatory guidance allows a greater
understanding of the method by the users, and leads to a
faster search of professionals or services, in case any compli-
cation is perceived. The most common side effects are:
• expulsion;
• pain or bleeding;
• perforation;
• infection;
• ectopic pregnancy; and
• topical pregnancy.
Signs of possible complications thatmay lead to the return
of patients to the doctor are the following:
• significant bleeding or abdominal pain within the first
three to five days after insertion may indicate perforation
at the time of insertion or the possibility of infection or
displacement of the LNG-IUS;
• irregular bleeding or pain in all cycles may correspond to
displacement or partial expulsion of the LNG-IUS;
• fever or chills with or without vaginal discharge may
indicate the presence of infection;
• persistent pain during sexual intercourse may relate to
infection, perforation or partial expulsion;
• menstrual delay with pregnancy symptoms or expulsion
of the LNG-IUS may indicate intra or extrauterine preg-
nancy, although rarely observed; and
• longer or non-visible LNG-IUS string may indicate dis-
placement of the device or even gestation.
LNG-IUS and Infections
Bacterial infections may appear because of endometrial
cavity contamination at the time of LNG-IUS insertion, and
although acute pelvic inflammatory disease (PID) is quite
rare, when it occurs, it is more common in the first 20 days
after insertion (C).39 Administration of doxycycline (200mg)
or azithromycin (1 g) an hour before insertion of the IUSmay
protect against pelvic infections, but the prophylactic use of
antibiotics should not be indicated for women at low risk for
sexually transmitted diseases who are candidates for LNG-
IUS insertion. On the other hand, in women with a potential
risk for bacterial endocarditis, antibiotic prophylaxis should
be used an hour before insertion or removal of the LNG-IUS.
During thefirst year of use, the infection rate is low for both
the LNG-IUS and TCu-380A. After three years, the rate of acute
PID in LNG-IUS users is lower than that of TCu-380A users
(0.5% and 2.0%, respectively). The low rate of acute PID in
young women under 25 years of age stands out. In patients
aged between 17 and 25 years, the difference is quite signifi-
cant,with an indexof 5.6% inTCu-380Ausers, and 0.3% in LNG-
IUS users (C).39 In conclusion, the risk of developing pelvic
inflammatory disease associated with IUDs is quite low and
related to the moment of insertion (B).40
LNG-IUS and Perforations
Perforations are rare complications occurring in 1.3 times
per 1,000 insertions. The careful insertion technique is the
main form of prevention (B).40 Perforation usually occurs
when the LNG-IUS is not inserted in the direction of the
uterine cavity, or when the cavity length (hysterometry) is
not measured correctly.
At the time of perforation, patients experience severe
pain, and the insertion procedure must be interrupted
immediately. The LNG-IUS must be removed through deli-
cate traction of the strings, which solves the vast majority of
cases. Perforation may be partial or complete. Pelvic ultraso-
nography, particularly the transvaginal one, is of great value
for the diagnosis of perforations, enabling a more appropri-
ate conduct in each case.
In cases of partial perforation, hysteroscopy is indicated to
remove the device when traction maneuvers of the strings
are not successful.
In complete perforations or beyond the uterine serosa,
laparotomy or laparoscopy are indicated to locate the LNG-
IUS and remove it (C).41
LNG-IUS and Ectopic Pregnancy
Anderson, Odlind and Rybo (A)36 found an ectopic pregnancy
rate of 0.2 women/year after 5 years of LNG-IUS use, com-
pared with 2.5 women/year in Nova-T (Bayer, Leverkusen,
Germany) users. Other studies have not observed the occur-
rence of ectopic pregnancies in patients using LNG-IUS.
These numbers represent a reduction of 80% to 90% in ectopic
pregnancy risk when compared with women not using
contraception. For ectopic pregnancy, the approximate Pearl
index is 0.02 per 100 women/year (D).33
Thus, the riskof ectopic pregnancy in LNG-IUS users is less
than 0.25% in 5 years of use (B).40
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LNG-IUS and Topical Pregnancy
Although pregnancy rates are extremely low, its occurrence
in women using the LNG-IUS requires adequate conduction
according to the location of the gestational sac in relation to
the LNG-IUS and the gestational age at the time of the
diagnosis (C).42
If the device strings are visible on specular examination
(gestation not greater than 12 weeks), they should be gently
removed by continuous and gentle traction. If the strings are
not visible on the specular examination, hysteroscopy per-
formed by an experienced and careful professional usually
solves most cases.
In cases of more advanced gestation, with the LNG-ISU
distant from the internal bore of the cervix, removal at-
tempts should be avoided, as the occurrence of failure is very
high. In these cases, advice for the pregnant woman is key,
bearing in mind it is a pregnancy with increased risk of
abortion, preterm labor and infections. In addition, it should
be monitored and examined frequently in the prenatal
routine or in the presence of any sign or symptom of
hemorrhagic and/or infectious complications.
LNG-IUS and Acne
The occurrence of acne (12%), weight gain (7%), depressive
mood (5%) and headache are minor side effects, and most
often do not require LNG-IUS removal for their treatment
(D).43 Severe cases are rare, and the user should be advised to
remove the LNG-IUS only when there is no clinical improve-
ment with the use of spironolactone (100 mg/day for 3
months) in mild and moderate cases, and/or Roaccutane
(Hoffman-La Roche, Basel, Switzerland) in cases of more
intense symptomatology (C).44
Copper Intrauterine Device
Intrauterine devices are the most known long-acting meth-
ods, and copper IUDs are the most widely used in the world
(D).45 The device’s mechanism of action is the alteration of
sperm motility and decrease of its viability caused by cervi-
cal mucus with high copper concentrations (C).46,47 In addi-
tion, increased leukocytes and cytokines in the uterine cavity
drastically reduce the likelihood of fertilization (A).48Despite
being scarcely used in Brazil (less than 5% of sexually active
women use IUDs), these methods are highly effective, low
cost, and easy to use (B).49,50
Copper-containing IUDs do not contain hormones, and the
most widely used types nowadays are the TCu-380 IUD and
the Multiload R375 IUD. They are more effective than other
models with lower copper concentrations that were used in
the past. Theyare easily inserted or removed and, at the same
time, do not require that the women or their partners
remember to use or apply them daily, enhancing the con-
traceptive effect (B).49
The TCu-380 IUD is probably the most widely used in the
world. It has a ten-year durability, and very low Pearl index
(one pregnancy or less in every 100 users in the first year of
use, and accumulating the rate of 3 out of every 100 users
after 5 years) (B).49 The cumulative pregnancy rate through-
out 20 years in a Brazilian clinic was 4 in every 100 women/
year (B).51 Large randomized clinical trials have shown
copper IUDs remain effective for 12 to 13 years (A).52
Insertion of Copper IUD
Traditionally, IUDs are inserted during the menstrual peri-
od, because the uterine cervix is believed to be discretely
dilated. However, the advantage of this practice is the
exclusion of pregnancy. Although unusual, IUDs can be
inserted at any point in the menstrual cycle if the pregnan-
cy is safely excluded. In addition, IUDs can be inserted
immediately after miscarriage, or in the immediate post-
partum period (A).52
For a long time, nulliparity was a reason for contraindi-
cating IUD use. However, recent studies have demonstrated
no greater difficulty in IUD insertion into nulliparouswomen
(failure rates of insertion are similar to those of multiparous
women), as well as similar acceptance, tolerability and pain
compared with women with previous pregnancies (B).53
Though this group is known to have a slight increase in
expulsion rates in the first 6 months (B),53 the World Health
Organization (WHO) currently considers it category 2 of the
eligibility criteria, that is, the benefits outweigh the possible
harm (D).12
Medications to Facilitate IUD Insertion
One of the main limiting factors for IUD use is pain during
insertion. Medications such as misoprostol (prostaglandin
inhibitor), non-steroidal anti-inflammatory drugs (NSAIDs),
and local anesthetics have been used to try to minimize this
pain. A recent systematic review found 15 randomized
clinical trials (A).54 The evidence did not show the insertion
was easier, neither a reduction in the need for techniques to
dilate the uterine cervix, nor higher success rates (A).54Only a
study with women who underwent a failed insertion proce-
dure showed higher success rates in the group that used
misoprostol prior to the procedure compared with the
placebo group (A).55 The use of diclofenac plus 2% intra-
cervical lidocaine also showed no positive effect on insertion
(A).56
Acceptability of the TCu-380 IUD
A recent Australian study followed a cohort of TCu-380 IUD
users to learn more about which women used the method.
Between 2009 and 2012, 211 women were monitored. One
third of the women were under 30 years of age, 36.5% had
never been pregnant, and the main reasons to choose the
methodwere effectiveness and not wanting to use hormonal
methods. The continuity ratewas 79.1% and 61.3% at the end
of 1 and 3 years respectively (B).57
IUD and Pelvic Inflammatory Disease
A classic concern of health professionals was the risk of
developing PID and consequently infertility in users of any
IUD. Because of this ‘myth,’ many felt it would be inappro-
priate to offer the method to women without a steady
partner, or to those who had never been pregnant. However,
studies have shown no correlation between the use of
intrauterine methods and a greater chance of developing
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PID. Therefore, the method can be offered to patients previ-
ously considered outside the eligible group for their use
(D).58,59
Irregular Bleeding with Copper IUD
It is unclear why copper IUDs increase uterine bleeding. This
may occur due to increased subendometrial vascularization
in users of this method (D).60 A comparative study between
users of TCu-380 and LNG-IUS showed greater uterine
bleeding in the first month after insertion of the TCu-380
with subsequent decrease until the third month, when the
menstrual pattern stabilizes (C).61 No study has shown
satisfactory results in the treatment of irregular bleeding
with copper IUD. Empirically, in an attempt to avoid prema-
ture removal of the IUD, clinicians have used NSAIDs (to try
to decrease vascular proliferation factors) or combined oral
contraceptives to stabilize the endometrium. One of the
causes of this bleeding may be infection and, if early-stage
PID is suspected, the use of broad-spectrum antibiotics can
improve irregular bleeding because they treat subclinical
endometritis.
Etonogestrel Implant
Implants are plastic devices placed under the skin that
continuously release progestogens. In Brazil, the only ap-
proved implant is IMPLANON, which is a single rod,  4 cm
long by 2 mm thick, containing 68 mg of etonogestrel (ENG)
(3-ketodesogestrel), the active metabolite of desogestrel,
involved in a non-radiopaque ethylene vinyl acetate (EVA)
membrane (B).62
The contraceptive effect is achieved mainly through con-
sistent ovulation inhibition (C).4 Alongside ovulation inhibi-
tion, ENG also causes alterations in the cervical mucus that
hinder sperm passage, as well as alterations in the endome-
trium, making it less suitable for nidation (C).63,64 On the
other hand, after the removal, the users’ serum levels become
undetectable within a week, then most women show ovula-
tion and are able to conceive within a few days after implant
removal (B).65
Indications for ENG implantation depend on the women’s
preference, on comorbidities in which estrogens cannot be
used, and on vulnerable groups such as adolescents, drug
addicts and women with HIV.
Management of Events and Adverse Events
A follow-up of more than 900 women for 3 years (C)66
showed that among general events, complaints of headache
(in 15% of patients) are more frequent during the first
6 weeks, when ENG release has a higher concentration
(60 to 70 mcg/day) (B).67,68 The headache usually occurs
at the end of the day without hemicrania characteristics
and, when necessary, common analgesics are effective (C).69
Another characteristic complaint of estrogenic action is
mastalgia (10%). However, in cases of implants, it is also
more frequent in the initial six-week period, generally
well-tolerated, requiring mostly the reassurance of no
risk of malignancy. If needed, common analgesics are effec-
tive (C).69
Ameta-analysis study found complaints regarding weight
gain from 12% of the patients. Importantly, this gain with
isolated progestogen methods is similar to that found in
women using other hormonal and non-hormonal contracep-
tive methods (A).70 The CHOICE study showed no difference
in weight gain among LARC (copper IUD, LNG-IUS and ENG
implant) users during the first year of follow-up (B).71
Therefore, if there is weight gain, women should be con-
sulted about any changes in lifestyle and diet (C).69
Acne as an adverse event was reported by 11% of the
users. The most likely women to complain about acne are
former users of the combined hormonal method. Because of
ethinyl estradiol (EE), such method greatly increases the sex
hormone-binding globulin (SHBG), considerably decreasing
free testosterone (B).72 The ENG-releasing implant, on the
other hand, has a neutral effect on the SHBG (C).63 There-
fore, the replacement of the EE method by the implant
causes SHBG levels to fall rapidly, increasing free testoster-
one. There is no study evaluating the use of anti-androgenic
drugs in the acne of the users of progestogen-only methods.
However, for the management of this adverse event, it is
possible to initially use 100 to 200 mg/day of spironolactone
and, if there is no improvement, 25 mg/day of cyproterone
acetate for 15 days/month or throughout the month, for
about 6 months (D).73
As the ENG-releasing implant does not inhibit the follicle-
stimulating hormone (FSH) (C),63,64 follicular cysts can occur
in 25% of the users after 12months (C),74 but these ovarian
cysts are benign, with no repercussion for the women, and
tend to disappear in 12 weeks. Usually, they are occasional
findings, and do not cause symptoms. However, if there is
abdominal pain, the use of non-steroidal analgesics or anti-
inflammatory drugs may be indicated (C).69
The main adverse event of the ENG-releasing implant, as
of any progestogen-only contraceptive, is the change in the
bleeding pattern and also the main cause for abandoning the
method.23,75 To discuss irregular bleeding, it is important to
know the patterns of vaginal bleeding induced by the con-
traceptive methods (C),76 taking into account the number of
days and the intensity of the vaginal bleeding or spotting
(spotting/bleeding of small quantity with use of at most one
pad or tampon/day) for a 90-day period, called reference
period (RP). The following are considered: 1) amenorrhea:
absence of bleeding in the RP; 2) infrequent bleeding: up to
three episodes (days) of bleeding in the RP; 3) normal
frequency: between three and five episodes of bleeding in
the RP; 4) frequent bleeding: more than five episodes in the
RP; 5) prolonged bleeding: more than 14 days of bleeding
(uninterrupted) in the RP.
Studies show these bleedings are usually well-tolerated
bywomen, provided they arewell-oriented prior to insertion
(B).23,75Amenorrhea, infrequent bleeding and regular bleed-
ing are considered a favorable bleeding pattern, while fre-
quent and prolonged bleeding is considered unfavorable. As
shown in►Table 2, the great majority of women presented a
favorable bleeding pattern, and only 20–25% presented an
unfavorable pattern (frequent or prolonged bleeding) (C)
(►Table 2).77,78
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How to Manage Irregular Bleeding?
• Guidance regarding the expected bleeding pattern prior
to the insertion (B).23,75
• Patience in thefirst 6months is key, since 50% of women
with an unfavorable pattern have a chance to improve
their bleeding pattern (C).78
• Rule out all other bleeding causes if the pattern remains
unfavorable after six months or associated pain appears
(B).79
• Treat as often as necessary, andwithmedications that can
be used and demonstrated in studies to be better than
placebo, though with different strength of evidence:79,80
• 30mcg of EE þ 150mcg of LNG for 1 to 3 cycles with or
without pause between cartons (A).
• Tranexamic acid 500 mg - 1,000 mg every 8 hours for
5–7 days (A). The treatment can be repeated as many
times as necessary, as long as they do not exceed 7 days.
• Doxycycline 100 mg every 12 hours for 5–7 days (C).
Here, the action is of decreasing metalloproteinases,
and not the known antibiotic action.
• Non-steroidal anti-inflammatory drugs (C). The most
studied were:
– Ibuprofen: 400 mg, every 8 hours for 5 days.
– Mefenamic acid: 500 mg, every 8 hours for 5 days.
– Celecoxib: 200 mg/day for 5 days.
• Estrogens (C): they have not shown to be better than
placebo at usual doses. Because of the decrease in
estrogen receptors, their action is difficult. Ethynil
estradiol 50 mcg/day was effective to decrease bleed-
ing in users of LNG-releasing implants.78
• Progestogens-only (D): even though to date there are
no studies comparing them to placebos, they have been
increasingly used:
• Desogestrel 75 mcg/day for 1–3 cycles.
• Norestisterone 10 mg every 12 hours for 21 days.
• Medroxyprogesterone acetate (MPA) 10 mg every
12 hours for up to 21 days.
Special Situations for Use of Long-acting
Contraceptive Methods
Adolescents and Nulliparous Women
After a decline in the past 15 years, the rate of teenage
pregnancy returned to grow for the first time in 2006 in the
USA, an increase of 3% over the rate of 2005 inwomen aged
between 15–19 years (B).1 Part of this can be explained by
the fact that the most popular contraceptive methods used
by adolescents depend on correct use for their effectiveness.
Adolescents want a safe and effective contraception
method, but find barriers to know and access the different
options, often because of the high initial cost.
Guidance to adolescents about contraception should in-
clude information on all available methods, including IUDs
and implants as first-line methods. However, many doctors
do not feel safe inserting IUDs and implants in adolescents
because they are not trained to do so. A study with predomi-
nantly medical professionals concluded that only 31% of
them considered IUDs an appropriate method for adoles-
cents; 50% would insert an IUD in a 17-year-old girl with a
child, and only 19% would insert it in an adolescent with the
same age without children, which goes totally against the
available guidelines (B).81
Currently, the most popular forms of contraception in
adolescents are condoms and thewithdrawalmethod (coitus
interruptus), followed by contraceptive pills (B).82 Only 3.6%
of women aged 15–19 years use IUDs. The use of less reliable
methods probably contributes to the 80% rate of unwanted
pregnancy among adolescents aged 15–19 years.
Age and parity are not contraindications to use LARCs.
Thus, they are indicated to adolescents and nulliparous
women (D).12
There are few studies of implants in adolescents. In a
retrospective study (2010–2013), Obijuru et al (B),83 evalu-
ated 116 records of adolescents using etonogestrel implants
who were in follow-up in an adolescent clinic.
Although in this group 39% of the participants reported
previous use of oral contraceptives, and 27% previous use of
DMPA, only 14% of the patients were using themethod at the
time of implant insertion.
Among them, 35% used only condoms, 42% did not use any
contraceptive method, only 3% used IUDs, and 3% used
implants. This means the majority of sexually active adoles-
cent (77%) patients were at risk of gestation, considering the
low efficacy of condoms as a contraceptive method.
Of the 116 participating patients, 94% were nulliparous,
and complete follow-up was available for 81% of them. The
authors considered as early removal of the implant if it
happened in less than 32 months. The implant continuity
rate at 12, 24 and 32 months was 78%, 50% and 40%
respectively.
Removal in less than 32 months occurred in 35% of the
cases. Early removal because of uncomfortable bleeding oc-
curred in 18% (17/94) of the patients. There was no significant
associationbetweenbodymass index,uncomfortablebleeding
and early removal of the implant. The results indicate the
continuity rate is high at 12 and 24 months, with 40% of
patients reaching 32 months of implant use, a significant
period of pregnancy protection (B).83
There are different guidelines for IUD use in adolescents.
In 2007, the committee of the American College of Obstetri-
cians and Gynecologists (D)84 recommended considering
IUDs as first-line options for contraception in adolescents
with or without children. The WHO also supports the use of
IUDs in adolescents by providing eligibility criteria 2
Table 2 Bleeding pattern with use of ENG-releasing implant
Bleeding pattern ENG implant%
Amenorrhea 22-40
Infrequent 30-40
Regular 20
Unfavorable pattern 6.7 frequent þ 17.7 prolonged
Abbreviation: ENG, etonogestrel.
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(benefits superior to risk) for women at menarche aged
20 years (D).12 The American Academy of Pediatrics (D)85
also considers IUDs to be safe in nulliparous adolescents, not
causing tubal infertility. Their removal is followed by the
rapid return of fertility.
Health professionals often do not identify adolescents as
potential candidates for using intrauterine methods. Part of
this thought results from the old fear that IUDs caused pelvic
inflammatory disease (PID) and tubal infertility, which would
be particularly worrying in childless adolescents. Current
evidence discards this association. The use of IUDs does not
increase the risk of pelvic inflammatory disease of the upper
genital tract above the baseline risk expected for women.
In addition to the unfounded fear of tubal infertility, the
IUD is often avoided in adolescents because of the thought of
its greater riskof expulsion and adverse effects in nulliparous
women compared with multiparous women. A study of 129
nulliparous LNG-IUD users found an expulsion rate of less
than 1% per year in women who had never been pregnant
(B).36 Other studies also found no increased risk of expulsion
in nulliparous women, nor a relationship with endometrial
cavity size measured by hysterometer or ultrasonography
(regardless of parity) (B).86
Immediate Postpartum Period and Post-abortion
Usually, the prescription of contraceptives in the puerperal
period occurs around six weeks after delivery (A).87 On the
other hand, the rates of missed postpartum consultations are
high, ranging from 10 to 40%, which makes many women
exposed to a new gestation (C).69 Despite the contraceptive
effectiveness of lactation and amenorrhea, in Brazil, the aver-
age period of exclusive breastfeeding is around 50 to 60 days
(median of 54 days) (C).88 Thus, it seems opportune that some
women initiate contraception still in the maternity, particu-
larly amongdrug users, distant dwellers, and thosewhowould
not have access to puerperium consultations. Long-acting
reversible contraceptives are alternatives for these women.
TheWHOrecommends theuseofall LARCs in thefirst48hours
after delivery, provided there are no contraindications to these
methods (D).12 In this situation, continuity rates at 12months
arehigh, and, in adolescentswhoused LARCs in the immediate
postpartumperiod, therewasmore than 80% reduction in the
risk of a new pregnancy in 1 year (B).89
The expulsion rates ofcopper IUDand LNG-IUS arehigher at
immediate postpartum insertion, and higher than the rates
observed in users of implants inserted in the postpartum
period (39% versus14% respectively) (B).90 Long-acting revers-
ible contraceptives inserted in the immediate postpartum
period appear not to affect lactation, growth, and neonatal
and infant development (A).91 The insertion of LARCs after
abortion is released if the womanwishes to become pregnant
(WHO), since ovulation occurs in more than 90% of women in
the month following the abortion (D).12
Drug Addiction
In Brazil, there are 370,000 peoplewho use crack or similar
drugs, of which 21% are women (78,000) and, of these, 13%
are pregnant (10,000) (C).92
Crack consumption has been directly associated with HIV
infection. The prevalence among women is double that of
men (C).92 In Cracolândia, an area in the central region of the
city of São Paulowhere crack users gather, 9% of women have
positive serology for HIV (B).93 The most frequent risk
behaviors in this population are the high number of partners,
unprotected sex, and the exchange of sex for drugs or money
to buy drugs, especially among sex workers (B).94–96
Compared with the general population, morbidity is
increased among female drug users with regard to abortions
(16.1%), fetal intrauterine death (1.7%) and prematurity
(20.6%) (B).93 Female drug users in Brazil had 3.4–3.8 preg-
nancies/woman, and birth rates of 2.6–2.9 live children/
woman (B).95
All these reasons determine the need to avoid pregnancies
in this vulnerable population due to the damages caused by
drugs, and because they are high-risk pregnancies. Much has
been written about the consequences of substance use
during pregnancy, but there has been much less focus on
preventing these unwanted pregnancies in women with
disorders with the use of opioid substances and their
derivatives.
The studies demonstrate the unmet contraception de-
mand, especially for the most effective methods, compared
with non-user women, such as long-acting reversible con-
traception, and barriers to easier access and use. A way to
alleviate the problem would be for institutions to treat the
use of substances in conjunction with services providing
contraception to promote the use of those methods (A).97,98
Approximately 35% of women who use drugs do not use
any contraceptive method (B).93 In a systematic review
performed in 2015 (6 studies), when opioid-user women
took contraception, they did it less frequently than non-users
(56% versus 81% respectively). The percentages of use varied
as follows: IUDs, 7%; implants, 15%; tubal ligation, 17%; oral
hormonal contraceptives, 17%; and quarterly injectable, 8%.
No study evaluated the vaginal ring or transdermal patch.
The use of moderately effective methods was observed as
follows: condom, 62%; diaphragm, 10%; sponge and natural
methods,  4%; and less effective methods, such as foam
(3%) and vaginal shower (23%). The condom is the most
widely used method because of its dual function of prevent-
ing sexually transmitted diseases (STDs) (A).97 In Brazil, the
efficacy of the methods should be adjusted with the avail-
ability of safe methods that do not depend on thewillingness
of female drug users to use them, given the difficulty in
tracing this population.
With regard to very effective methods, tubal ligation can
be performed as long as it is available in the basic health
network, within established clinical criteria, and with in-
formed and signed consent, avoiding the criticisms of the
movements contrary to the ‘sterilization’ process (D).99
Despite the difficulties in access and the rapid return of
fertility after the time of use, LARCs can be offered (A).98
When using copper or levonorgestrel IUDs, the risk of
pelvic inflammatory disease should be considered, given the
difficulty of performing pre-insertion examinations and
tracking patients (B).100 The etonogestrel implant can be
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used, and it promotes safe protection against unwanted
pregnancy (B).93
As short-duration methods are difficult to use in drug
users and have a 9% real failure rate, they should be avoided
(A).9 Although the quarterly injectable method has up to 3%
of failure rate, it can be an option, but it needs active control
of health agencies (A).9 Condoms should always be recom-
mended and offered, given the risks of sexually transmitted
diseases.
Ethical and Legal Aspects for the Procedure of
Inserting Long-acting Methods in Adolescents
In Brazil, the use of the informed consent form (ICF) in
studies involving human beings was first proposed by Reso-
lution number 01/88 of the Brazilian National Health Coun-
cil, and the entire chapter IVof Resolution 196/96-CNS/MS is
dedicated to it.101 Although the ICF was more widely used in
clinical trials, the value of consent was extended to routine
medical care situations. Thus, in article 1 of January 21 2016
(Federal Council of Medicine recommendation 1/2016), it is
emphasized that physicians should consider the ICF in
decisions about patient health care.102
The insertion of LARCs is characterized as a medical
procedure; hence, it could follow the precepts of establishing
the informed consent. Age is the main controversial point,
because there are differences in the interpretation of laws
involving adolescents. The WHO characterizes adolescence
as the second decade of life (10 to 19 years), and youth as the
period between 15 and 24 years of age. The Brazilian Statute
of the Child and Adolescent, in Article 2, considers people
aged up to 12 incomplete years as children, and those aged
between 12 and 18 years as adolescents. The Brazilian Civil
Code, in turn, considers the age of 18 years for the practice of
all acts of civil life. People older than 16 years can reach
civilian majority for certain acts (emancipation, marriage,
exercise of effective public employment, etc.).103
The Brazilian Statute of the Child and Adolescent pre-
serves privacy, confidentiality and informed consent as
fundamental rights. The ‘family power’ (old parens patriae)
of the parents or legal guardians is not an absolute right.104
However, in Brazil, according to the new article 217-A of
the penal code modified by law 12.015/2009, article 3, the
age of consent for sex is 14 years. Article 217-A of the
Criminal Code defines as ‘rape of a vulnerable’ the act of
‘having carnal conjunction’ or practicing libidinous acts with
somebodyaged under 14 years, regardless if real violencehas
occurred. That is, if a minor under 14 years of age engages in
any sexual act, it may be considered sexual violence, even if
the act was performed on one’s own free will.105
Article 228 of the Brazilian Federal Constitution estab-
lishes that “minors under 18 years of age are criminally
unimputable, subject to the norms of a special legislation,”
and, in accordance with the constitutional norm, the Statute
of the Child and Adolescent infraction regime does not follow
the typical system of Criminal Law based on criminal types
and minimum and maximum penalties for each offense. The
Statute of the Child and Adolescent does not refer to penal-
ties or crimes practiced by adolescents, mentioning only
infractions and social and educational measures that are not
individualized for each specific conduct. There is no refer-
ence to “criminal liability” in the Statute of the Child and
Adolescent.103
The Brazilian Pediatric Society (SBP, in the Portuguese
acronym) and the Brazilian Federation of Gynecology and
Obstetrics Societies (FEBRASGO, in the Portuguese acronym)
have prepared a document stating that the “prescription of
contraceptive methods” should take into account the ado-
lescents’ request, and respect medical eligibility criteria
regardless of age. The prescription of contraceptive methods
for adolescents younger than 14 years of age is no unlawful
act of the physician, as long as the aforementioned criteria
are respected. In the care of sexually active adolescents
younger than 14 years, there is no longer the presumption
of rape, as long as there is professional knowledge that it is
not happening, based on information provided by the ado-
lescent and careful evaluation of the case, all of which must
be duly recorded in the patients’ medical record (D).106
As this is a difficult issue, the Women’s Health Reference
Center (in the city of São Paulo) provided an alternative to
this situation by adopting a term of consent for adolescents
aged younger than 15 years using an etonogestrel subdermal
implant as contraceptive. The document is signed by the
adolescent, and has the same guidelines contained in the ICF,
although more appropriate to that age, in addition to the
regular ICF signed by the legal guardian (B).93
In conclusion, since there are many doubts in this situa-
tion, the consent of the adolescents and the legal guardians
are considered for the use of LARCs, reinforcing the con-
traceptive counseling and suggesting the use of the ICF. These
aspects still need further debate among the involved socie-
ties and public bodies.
Final Recommendations
1. Long-acting reversible contraceptives include the copper
IUD, the LNG-IUS and the etonogestrel implant (D).
2. Long-acting reversible contraceptives have greater con-
traceptive efficacy compared with short-duration meth-
ods (B).
3. Long-acting reversible contraceptives have greater ac-
ceptance and continuity rates, and less contraindications
compared with short-duration methods (A).
4. Anticipatory guidance about the bleeding pattern in each
method is key, because, although low, discontinuity of the
use of LARCs is mainly due to irregular bleeding (B).
5. Intrauterine methods do not increase the risk of PID (B).
6. Intrauterine methods may be indicated to women with
history of ectopic pregnancy (B).
7. The LNG-IUS and the etonogestrel implant may be indi-
cated for lactating women, including during the imme-
diate postpartum period, because they are not related to
thromboembolic events, and do not affect milk produc-
tion and the infants’ growth and development (A).
8. The postpartum insertion of intrauterine methods is
associated with a higher expulsion rate (B).
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9. Long-acting reversible contraceptives can be indicated to
adolescents and nulliparous women (B).
10. Intrauterine methods and the etonogestrel implant do
not increase the risk of venous thromboembolism (A).
11. The etonogestrel implant plays an important role in the
contraception of vulnerable groups, such as drug users
and homeless people (B).
12. The insertion of LARCs in adolescents should be per-
formed after consent of the legal guardian aswell, and the
ICF can be used (D).
13. The main barriers for the use of LARCs are related to
access and cost. Training the health professionals, pro-
viding proper guidance in particular, is also fundamental
to reduce the barriers and expand the access to LARCs (B).
Conclusion
Long-acting reversible contraceptives are more effective
contraceptive methods than short-acting contraceptive
methods. They present a higher continuity rate, and have a
small number of contraindications. Irregular bleeding is the
main cause of discontinuation. They can be indicated for
nulliparous women and adolescents, and can be inserted in
the postpartum or immediate post-abortion. Intrauterine
methods are not associated with increased risk of PID,
provided that the technical rigors of insertion are observed.
The main barriers to the use of LARCs are access and cost.
Health professionals involved in contraceptive measures
should prioritize appropriate guidance and training to offer
and recommend LARCs.
Note
This study ispartof theGuidelines andRecommendationsof
the FEBRASGO, and its authors aremembers of the Brazilian
National Specialized Commission in Contraception.
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